Medication Monitor



Generic Name (Trade Name—Company)
Notes
September 21, 2019

Mepolizumab

(Nucala—GlaxoSmithKline)
Biologic now approved for treatment of children ages 6 to 11 years with severe eosinophilic asthma

FDA has approved mepolizumab for use in children as young as 6 years old who have severe eosinophilic asthma. It is the only targeted biologic to be approved for the condition in the 6- to 11-year-old age group in the United States. 

First approved in 2015 for severe eosinophilic asthma, mepolizumab is a first-in-class monoclonal antibody that targets IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils. Inhibiting IL-5 binding reduces blood eosinophils without completely depleting them.

For severe asthma in patients aged 6 to 11 years, the recommended dosage is 40 mg administered subcutaneously once every 4 weeks.

The most common adverse reactions include headache, injection site reaction, back pain, and fatigue.